Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Song Wen, Thiquynhnga Nguyen, Min Gong, Xinlu Yuan, Chaoxun Wang, Jianlan Jin & Ligang Zhou. (2021) An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is). Diabetes, Metabolic Syndrome and Obesity 14, pages 2955-2972.
Read now
Read now
Articles from other publishers (9)
Kosar Malekpour, Ali Hazrati, Sara Soudi, Leila Roshangar, Ali Akbar Pourfathollah & Majid Ahmadi. (2023) Combinational administration of mesenchymal stem cell-derived exosomes and metformin reduces inflammatory responses in an in vitro model of insulin resistance in HepG2 cells. Heliyon 9:5, pages e15489.
Crossref
Crossref
Theocharis Koufakis, Evangelos N. Liberopoulos, Alexander Kokkinos, Pantelis Zebekakis & Kalliopi Kotsa. (2023) Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?. Drugs 83:6, pages 469-477.
Crossref
Crossref
Simone A. Melander, Anna Katri, Morten A. Karsdal & Kim Henriksen. (2023) Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin. European Journal of Pharmacology 938, pages 175397.
Crossref
Crossref
Nour-Mounira Z. Bakkar, Ibrahim AlZaim & Ahmed F. El-Yazbi. (2022) Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. Clinical Science 136:22, pages 1631-1651.
Crossref
Crossref
Tingting Liang, Xinqiang Xie, Lei Wu, Longyan Li, Lingshuang Yang, He Gao, Zhenshan Deng, Xiangqian Zhang, Xuefeng Chen, Jumei Zhang, Yu Ding & Qingping Wu. (2022) Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis. Frontiers in Nutrition 9.
Crossref
Crossref
Marla J. Hayes. (2022) Overcoming Therapeutic Inertia in Type 2 Diabetes: Combination GLP-1 Agonist and SGLT-2 Inhibitor Therapy Offers Hope. ADCES in Practice 10:3, pages 32-34.
Crossref
Crossref
José Ignacio Martínez-Montoro, José Luis Pinzón-Martín, Miguel Damas-Fuentes, Andrea Fernández-Valero & Francisco J. Tinahones. (2022) Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report. Frontiers in Endocrinology 13.
Crossref
Crossref
Pavel H. Lugo-Fabres, Leslie M. Otero-Sastre, Johanna Bernáldez-Sarabia, Tanya A. Camacho-Villegas, Noemi Sánchez-Campos, Janeth Serrano-Bello, Luis A. Medina, Saé Muñiz-Hernández, Lizbeth de la Cruz, Isabel Arenas, Antonio Barajas-Martínez, David E. Garcia, Linda Nuñez-Garcia, Jorge González-Canudas & Alexei F. Licea-Navarro. (2021) Potential Therapeutic Applications of Synthetic Conotoxin s-cal14.2b, Derived from Californiconus californicus, for Treating Type 2 Diabetes. Biomedicines 9:8, pages 936.
Crossref
Crossref
Burkhard Göke. (2020) Die Behandlung des Diabetes mellitus: Mythen und EvidenzThe treatment of diabetes mellitus: myths and evidence. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 63:5, pages 512-520.
Crossref
Crossref